Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmaceutical Care Program for Type 2 Diabetes Mellitus (pcp)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02435693
Recruitment Status : Completed
First Posted : May 6, 2015
Last Update Posted : November 4, 2015
Sponsor:
Information provided by (Responsible Party):
TABREJ MUJAWAR, R. C. Patel Institute of Pharmaceutical Education & Research

Brief Summary:

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

  1. To evaluate Pharmaceutical care program in Type2 diabetics.
  2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.
  3. To study the prevalence of Type2 diabetics cases in Dhule.
  4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.
  5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.
  6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus.
  7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule.
  8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus.
  9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's.
  10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Condition or disease Intervention/treatment Phase
DIABETES MELLITUS, TYPE 2 Other: PHARMACEUTICAL CARE programe Other: Without PHARMACEUTICAL CARE programe Not Applicable

Detailed Description:

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule
Study Start Date : July 2012
Actual Primary Completion Date : June 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PHARMACEUTICAL CARE programe
The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
Other: PHARMACEUTICAL CARE programe
The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

control
without pharmaceutical care programe (control)
Other: Without PHARMACEUTICAL CARE programe



Primary Outcome Measures :
  1. Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded [ Time Frame: 24 weeks ]
    Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose


Secondary Outcome Measures :
  1. Quality of Life score [ Time Frame: 24 weeks ]
    Quality of Life score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Inclusion Criteria:

  • Patients with type 2 diabetes mellitus of either
  • Patients with HbA1c more than 7% and
  • Patients with blood sugar level more than 140 mg / dl

Exclusion Criteria:

  • Patient with end stage kidney disease.
  • Patient with heart failure.
  • Patient with chronic Diabetes problem and orthopedic problem

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02435693


Locations
Layout table for location information
India
Tabrej Aj Mujawar
Dhule, Maharashtra, India, 424001
Sponsors and Collaborators
TABREJ MUJAWAR
Investigators
Layout table for investigator information
Principal Investigator: tabrej aj mujawar, mpharm muhs
Layout table for additonal information
Responsible Party: TABREJ MUJAWAR, tabrej mujawar mpharm Study principal investigator, R. C. Patel Institute of Pharmaceutical Education & Research
ClinicalTrials.gov Identifier: NCT02435693    
Other Study ID Numbers: pc
First Posted: May 6, 2015    Key Record Dates
Last Update Posted: November 4, 2015
Last Verified: November 2015
Keywords provided by TABREJ MUJAWAR, R. C. Patel Institute of Pharmaceutical Education & Research:
pharmaceutical care
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases